Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure: a retrospective study

Figures & data

Table 1 Patient demographics

Characteristics	N (%)
Age (years)
Median (range)	63 (39–79)
Sex
Male	12 (44.4%)
Female	15 (55.6%)
Smoking history
Never	24 (88.9%)
Former or current	3 (11.1%)
Tumor stage
IV	27 (100%)
ECOG PS
0	4 (14.8%)
1	10 (37.0%)
2	12 (44.5%)
3	1 (3.7%)
Histology
Adenocarcinoma	23 (85.2%)
Squamous cell carcinoma	3 (11.1%)
Large cell carcinoma	1 (3.7%)
EGFR mutation status
Sensitive mutation	23 (85.2%)
Not detected	4 (14.8%)
Line of apatinib plus icotinib treatment
Second-line	14 (51.9%)
Third- or later-line	13 (48.1%)
Time of icotinib monotherapy failure
≤6 months	11 (40.8%)
>6 months	16 (59.2%)

Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor.

Figure 1 PFS in 27 patients with advanced NSCLC after apatinib plus icotinib treatment following icotinib monotherapy failure.

Abbreviations: mPFS, median progression-free survival; NSCLC, non-small cell lung cancer; PFS, progression-free survival.

Figure 2 (A) PFS in 14 patients after apatinib plus icotinib treatment as the second-line therapy and in 13 patients after apatinib plus icotinib treatment as the third- or later-line therapy. (B) PFS in 11 patients who experienced icotinib monotherapy failure within 6 months and in 16 patients who experienced icotinib monotherapy failure after more than 6 months.

Abbreviations: mPFS, median progression-free survival; PFS, progression-free survival.

Table 2 Adverse events

Adverse events	N (%)
Hypertension	12 (44.4)
Fatigue	10 (37.0)
Hepatic injury	8 (29.6)
Anorexia	6 (22.2)
Hand-foot syndrome	5 (18.5)
Nausea	3 (11.1)
Palpitation	1 (3.7)
Diarrhea	1 (3.7)